InvestorsHub Logo
Followers 5
Posts 1109
Boards Moderated 0
Alias Born 05/02/2014

Re: Adrock post# 21685

Monday, 04/13/2015 1:38:16 PM

Monday, April 13, 2015 1:38:16 PM

Post# of 140475
Both the articles on SA, for Transenterix and Titan, exhibit serious weaknesses in regard to medical/surgical understanding.

For example, Surgibot was continually referred to as a robotic system; it really is not. It's just an extended set of passively elongated laproscopic handles. Imaging is not even "integrated" in the sense that the surgeon is viewing a separate screen at distance through goggles. This technology was compared with apparent equality to daVinci which at minimum offers serious ergometric and instrument control advantages to the surgeon.

Titan's article ignorantly contrasts SPORT in terms of market-experience time with Mazor. They are two different sytems designed for two different purposes.

I think both articles are pretty lame.

I note that they mentioned a JJ/Google acquisition is not out of the realm of possibility.

Also note that they speak of the ample war chest available to ISRG. I'd like to see Titan trying to add NOW to their reserve of cash which they could use to advantage in this last stage before rollout and trials.